Of about 330 registered psilocybin trials, 120 name depression and 52 name no patient condition at all.

Sixty-six trials give psilocybin to healthy volunteers to observe what it does in the body. Fourteen of those also name a patient condition, eight of them depression, so the number that names no patient condition at all is 52 of 327. A healthy-volunteer study measures how a drug behaves in people who have no condition to treat.

Every number here counts a registration, a sponsor filing a protocol on a public registry to say what it intends to study. Some have published and others never will, so counting them measures where money and attention went and says nothing about outcomes.

A registry also leaves out laboratory work and case reports by design, so when a group holds few trials, that says few registered human protocols exist and carries no verdict on the idea. These are counts of trials, never of patients: the smallest study in the register enrolled four people (opens in new tab) and the largest is registered to enrol a thousand (opens in new tab), and each is one row.

The honest answer is a small number. Anxiety holds 18 registrations of 327, OCD 12, eating disorders 8 and bipolar disorder 4, totals small enough that two or three new filings would visibly change the picture, which is why we will not tell you which way any of them is moving. It is not that we have a view we are keeping back. At those numbers there is nothing yet to see.

Your condition may still be in the register, because seventeen trials match none of our groups and their condition strings are more varied than the eleven suggest: post-treatment Lyme disease (opens in new tab), irritable bowel syndrome, burnout in physicians, caregiver distress, aging and longevity, self-harm, stable ischaemic heart disease. We drew the eleven groups. Medicine did not. Search the register by your own condition and treat this table as a summary, and if you want to know whether any of this is open to you, the trials in the recruiting stage are listed separately.

It did not, because depression grew along with everything else. Split the register by start date and 99 trials are dated 2022 or earlier and 222 are dated 2023 or later. Four groups grew faster than depression did: neurological conditions went from 3 to 18, PTSD from 6 to 24, addiction and substance use from 12 to 40, and cancer and end-of-life care from 7 to 18.

Depression went from 35 to 82, while every other trial in the register went from 64 to 140. That is a factor of 2.34 against 2.19, so the largest category in the field expanded slightly faster than all the others combined.

The register here is our own corpus as it stood in August 2026, which merges three public trial registries (ClinicalTrials.gov (opens in new tab), the EU’s Clinical Trials Information System (opens in new tab) and the ISRCTN registry (opens in new tab)) and holds 327 rows. Groups come from our condition taxonomy, condition_groups v2026-08-20.

Trials dated 2023 or later also name more conditions each, 1.20 groups per trial against 1.12 among the earlier ones, which is part of why every category looks larger. That is why this piece compares growth rates: shares of trials do not sum to 100 here, so no group’s rise takes anything from another. Depression is measured against the rest of the register, since measuring it against the whole would compare it partly with itself.

Two readings cut against ours. The fastest-growing categories are the ones carrying large public funding streams, so this may be a map of grant money that is only incidentally a map of the science. And small starting cells make unstable factors: neurological conditions grew sixfold on three trials becoming eighteen, and depression’s own margin, 2.34 against 2.19, is narrow enough that a handful of rows either way would close it.